341 related articles for article (PubMed ID: 27998711)
1. Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases.
Bishop KM
Neuropharmacology; 2017 Jul; 120():56-62. PubMed ID: 27998711
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic modalities to address nondrugable protein interaction targets.
De Souza EB; Cload ST; Pendergrast PS; Sah DW
Neuropsychopharmacology; 2009 Jan; 34(1):142-58. PubMed ID: 18754007
[TBL] [Abstract][Full Text] [Related]
3. The potential of antisense as a CNS therapeutic.
Godfray J; Estibeiro P
Expert Opin Ther Targets; 2003 Jun; 7(3):363-76. PubMed ID: 12783572
[TBL] [Abstract][Full Text] [Related]
4. Society for Neuroscience--38th Annual Meeting--Data for therapeutics for CNS diseases and disorders.
Macauley D; Al-Shamahi A
IDrugs; 2009 Jan; 12(1):17-9. PubMed ID: 19127499
[No Abstract] [Full Text] [Related]
5. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases.
O'Sullivan S; Dev KK
Neuropharmacology; 2017 Feb; 113(Pt B):597-607. PubMed ID: 27825807
[TBL] [Abstract][Full Text] [Related]
7. The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.
Gribkoff VK; Kaczmarek LK
Neuropharmacology; 2017 Jul; 120():11-19. PubMed ID: 26979921
[TBL] [Abstract][Full Text] [Related]
8. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
Cole PE; Schwarz AJ; Schmidt ME
Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound.
Poon C; McMahon D; Hynynen K
Neuropharmacology; 2017 Jul; 120():20-37. PubMed ID: 26907805
[TBL] [Abstract][Full Text] [Related]
10. Dendrimer advances for the central nervous system delivery of therapeutics.
Xu L; Zhang H; Wu Y
ACS Chem Neurosci; 2014 Jan; 5(1):2-13. PubMed ID: 24274162
[TBL] [Abstract][Full Text] [Related]
11. A single-cell map of antisense oligonucleotide activity in the brain.
Mortberg MA; Gentile JE; Nadaf NM; Vanderburg C; Simmons S; Dubinsky D; Slamin A; Maldonado S; Petersen CL; Jones N; Kordasiewicz HB; Zhao HT; Vallabh SM; Minikel EV
Nucleic Acids Res; 2023 Aug; 51(14):7109-7124. PubMed ID: 37188501
[TBL] [Abstract][Full Text] [Related]
12. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
Banks WA
Nat Rev Drug Discov; 2016 Apr; 15(4):275-92. PubMed ID: 26794270
[TBL] [Abstract][Full Text] [Related]
13. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
Monine M; Norris D; Wang Y; Nestorov I
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
[TBL] [Abstract][Full Text] [Related]
14. Thiazole: a promising heterocycle for the development of potent CNS active agents.
Mishra CB; Kumari S; Tiwari M
Eur J Med Chem; 2015 Mar; 92():1-34. PubMed ID: 25544146
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials in CNS--SMi's eighth annual conference.
Kirk R
IDrugs; 2010 Feb; 13(2):66-9. PubMed ID: 20127552
[TBL] [Abstract][Full Text] [Related]
16. Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.
Amigoni F; Legnaghi E; Pevarello P
Pharm Pat Anal; 2012 May; 1(2):177-92. PubMed ID: 24236782
[TBL] [Abstract][Full Text] [Related]
17. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of sigma (σ) receptors for the treatment of central nervous system diseases: evaluation of the evidence.
Banister SD; Kassiou M
Curr Pharm Des; 2012; 18(7):884-901. PubMed ID: 22288410
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides for target validation in the CNS.
Ho SP; Hartig PR
Curr Opin Mol Ther; 1999 Jun; 1(3):336-43. PubMed ID: 11713799
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the search for drugs to treat central nervous system disorders.
Enna SJ; Williams M
J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
